BA
ACRS icon

BlackRock Advisors’s Aclaris Therapeutics ACRS Stock Holding History

BlackRock Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$184K Buy
6,784
+2,234
+49% +$57K ﹤0.01% 2754
2016
Q3 		$117K Buy
4,550
+1,686
+59% +$35.8K ﹤0.01% 2955
2016
Q2 		$53K Buy
2,864
+927
+48% +$18.4K ﹤0.01% 3212
2016
Q1 		$37K Hold
1,937
– – ﹤0.01% 3254
2015
Q4 		$52K Buy
+1,937
New +$37.7K ﹤0.01% 3173

Other funds holding ACRS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SMV
Sofinnova Management VIII Menlo Park, California $183M AUM 4.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock Advisors's ACRS Position: Q4 2016 in Review

BlackRock Advisors increased its Aclaris Therapeutics (ACRS) stake by 49% in Q4 2016, buying an estimated $57K and bringing the position to 6,784 shares worth $184K. The position accounts for ﹤0.01% of the portfolio, ranked #2754.

BlackRock Advisors first reported a position in ACRS in Q4 2015 and has held it in 5 quarters since. 100 funds tracked by Wall St. Rank hold ACRS as of Q4 2016.

  • BlackRock Advisors held 6,784 shares of Aclaris Therapeutics worth $184K as of Q4 2016.
  • BlackRock Advisors bought 2,234 Aclaris Therapeutics shares in Q4 2016, an estimated $57K.
  • Aclaris Therapeutics made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #2754 holding.
  • BlackRock Advisors first reported a position in Aclaris Therapeutics in Q4 2015 and has held it in 5 quarters since.
  • 100 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.